Examining Safety, Efficacy and Feasibility of Preoperative Propranolol in Patients With PDAC. (IMPULS)

Examining the Impact of Propranolol on Preoperative Anxiety and on Tumorigenic Changes in Patients With Pancreatic Ductal Adenocarcinomas: a Randomized, Triple-blinded, Placebo-controlled Pilot Trial

The IMPULS trial is a randomized, triple-blinded, placebo controlled, single center, pilot trial examining the efficacy and safety of preoperative propranolol in patients scheduled for pancreatic cancer surgery. The study is conducted as a type 1 hybrid efficacy-implementation trial of 30 patients.

This study is designed to provide pilot data for a future larger perioperative study of propranolol with the aim of improving outcomes for pancreatic cancer surgery.

In total, 30 participants will be allocated in a 1:1 ratio with 15 participants enrolled in each trial arm (propranolol vs. placebo). Participants will be allocated to either 40 mg propranolol twice daily or placebo twice daily in 10 days prior to planned surgery.

Primary outcomes: Evaluating the efficacy of preoperative propranolol on anxiety and in pro-tumorigenic changes (e.g., in the tumor tissue and in blood samples) in patients undergoing surgery for pancreatic cancer. Furthermore, to obtain follow up data (e.g., 90-day mortality, postoperative complications etc. on the patients receiving propranolol versus placebo). Heart rate variability among the participants will also be examined.

Secondary: Examining the safety and tolerability of 40 mg preoperative propranolol twice daily in patients undergoing surgery for pancreatic cancer.

Tertiary: Evaluating the feasibility and implementation of the trial (using the APEASE framework). This will help identify barriers and enablers to a future larger study.

Short-time propranolol treatment is considered safe with a mild and manageable safety-profile. Risk-management, mitigations and guidelines to ensure patient safety is included in the protocol. Since this clinical trial is exploratory in nature, no sample-size calculation is performed.

Study Overview

• Status: Recruiting
• Conditions: Pancreatic Cancer; Surgery
• Intervention / Treatment: Drug: Placebo; Drug: Propranolol

Detailed Description

The study will be conducted as a pilot study to test efficacy, safety and feasibility of propranolol on preoperative anxiety in patients undergoing abdominal surgery for suspected pancreatic ductal adenocarcinoma (PDAC). Furthermore, the implementation of the trial including compliance of the participants in a hybrid type 1 setup will be examined.

A total of 30 participants will be included and randomized to receive either propranolol or placebo twice daily with 15 patients in each arm. Following this study, a power calculation will be done to reveal the actual number of needed participants in each arm for a potential follow-up randomized clinical trial on primary outcomes of interest. Thus, the results from this study can be used for future power calculations for clinical trials related to this topic.

Primary objectives: Efficacy

Evaluating the efficacy of preoperative propranolol on patient-experienced anxiety and on tumorigenic gene expression compared to placebo is the primary objective of this trial.

Primary objectives are further divided in to primary clinical objectives, primary translational objectives and exploratory endpoints.

Primary clinical objectives:

The primary clinical objectives are to evaluate preoperative patient-experienced anxiety in patients receiving the nonselective beta-2-adrenergic receptor inhibitor, propranolol, compared to placebo.

Further, heart rate variability (HRV) will be measured in order to evaluate changes in the autonomous nervous system in relation to surgery. HRV is calculated from the interval variation between consecutive R waves in an ECG time series and results suggest that it is associated with the intra- and postoperative complications. As HRV reflects sinoatrial node regulation, it is expected to be affected by the beta-adrenergic blockade caused by preoperative propranolol. Analyzing this relation will provide essential knowledge in understanding how HRV behaves perioperatively.

Lastly, follow up on the participants receiving propranolol compared to placebo will be done.

Primary clinical effect parameters:

The following primary effect parameters will be used to investigate the primary clinical objectives:

• Anxiety levels will primarily be measured by The Hamilton Anxiety Rating Scale (HAM-A) and secondarily by The Hospital Anxiety and Depression Scale (HADS). The European Organization for Research and Treatment of Cancer (EORTC) quality of life questionnaire (QoL) for pancreatic cancer will be used to assess quality of life.
• HRV is calculated from continuous ECG gathered by a Holter monitor. The monitor is a small wearable apparatus with one lead, placed on the patient's sternum. It is applied on preoperative day 9 and will run continually until approximately postoperative day 7. The actual calculations are achieved post hoc using software specialized for HRV analysis.
• Follow up at 30- and 90-days after surgery including parameters such as survival and postoperative complications.
• Long-term follow up at as 1-year, 3- year and 5-year following surgery including survival and recurrence data.

Primary translational objectives:

The primary translational objectives are to examine the systemic (biochemical) and local changes (TME of resections) to propranolol treatment compared to placebo. Alterations in pro-metastatic and proinflammatory genes will specifically be analyzed.

Primary translational effect parameters:

• Blood sampling for the analysis of pro-metastatic and proinflammatory biomarkers.
• Expression of pro-metastatic and proinflammatory genes in formalin-fixed paraffin-embedded (FFPE) cancer tissue obtained after surgical resection.

Exploratory endpoints:

The potential influence of inter-participant genetic variations (pharmacogenetics) on measured levels of serum propranolol and response to surgical stress will be investigated as exploratory endpoints. The differences in drug metabolism (pharmacokinetics) among participants will also be of interest.

Secondary objectives: Safety

Secondarily, tolerance and safety of the intervention in this pilot study (e.g., adverse effects, number of patients that need dose reduction etc.) will be evaluated. Changes in heart rate (HR) and blood pressure (BP) during the intervention period will be examined to test safety and tolerability of preoperative propranolol.

Secondary effect parameters:

• Measuring the changes in resting HR and BP during the intervention period with handed out blood pressure monitors.
• Safety endpoints: light-headedness, lethargy, hypotension, bradycardia and other symptoms and side-effects that may be related to propranolol treatment.

Tertiary objectives: Feasibility

Additionally, the feasibility of this intervention using the APEASE framework, which assesses factors like affordability, practicability, effectiveness, acceptability, side-effects, and equity, thereby determining the willingness to adopt this strategy will be examined. This will help identify barriers and enablers to a future larger study. The details regarding the APEASE framework are described under assessments.

This trial will be conducted in accordance with the principles of Good Clinical Practice and reported according to the CONSORT and the complimentary StaRI standards for implementation studies.

• Study Type: Interventional
• Enrollment (Estimated): 30
• Phase: Phase 2

Contacts and Locations

• Study Contact: Name: Ismail Gögenur, Professor; Phone Number: +4547323181; Email: igo@regionsjaelland.dk
• Study Contact Backup: Name: Adile Orhan, MD; Phone Number: +4560807762; Email: aor@regionsjaelland.dk

Study Locations

• Denmark
  • København, Denmark, 2200
    • Recruiting
    • Department of Surgical Gastroenterology
    • Contact: Stefan K Burgdorf, MD, PhD; Phone Number: +4535458225; Email: stefan.kobbelgaard.burgdorf.02@regionh.dk
  • Køge, Denmark, 4600
    • Not yet recruiting
    • Ismail Gögenur
    • Principal Investigator: Ismail Gögenur, Professor
    • Contact: Adile Orhan, MD; Phone Number: +4560807762; Email: aor@regionsjaelland.dk
    • Contact: Ismail Gögenur, Prof.; Phone Number: +4547323181; Email: igo@regionsjaelland.dk
    • Principal Investigator: Adile Orhan, MD

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: Adult; Older Adult
• Accepts Healthy Volunteers: No

Description

Inclusion Criteria:

• Patients with suspected surgically resectable pancreatic cancer
• Indication for surgical treatment with curative intend.
• Provide written informed consent.
• Patients minimum 18 years old.

Women of childbearing potential (WOCBP) are defined as women ranging from the period of menarche till the post-menopausal period, unless permanently sterile (e.g., hysterectomy, bilateral salpingectomy and bilateral oophorectomy). Post-menopause is defined as no menses for 12 months without an alternative medical cause.

WOCBP should use a secure and highly effective birth control (as stated in the "Recommendations related to contraception and pregnancy testing in clinical trials", version 1.1., section 4.1, from the Clinical Trials Facilitation and Coordination Group) during the entire period of the trial. In cases of uncertainty regarding pregnancy, additional pregnancy testing either as highly sensitive serum or urine pregnancy test can be used.

Exclusion Criteria:

• Patients with:
• Chronic hypotension, systolic blood pressure < 100 mg Hg for women and < 110 mg Hg for men.
• Bradycardia, pulse < 50 beats per minute.
• Asthma or chronic obstructive lung disease
• Heart insufficiency with affected (< 50 %) left ventricle ejection fraction (LVEF), treated or untreated.
• Kidney insufficiency, defined as eGFR < 20 ml/min.
• Liver insufficiency defined as chronically high liver enzymes or known chronic liver disease (e.g., hepatitis, steatosis, cirrhosis).
• Cor pulmonale
• Cardiogenic shock
• Severe peripheral circulatory disorders
• Known or newly diagnosed current metabolic acidosis (e.g., in recent analysis of arterial puncture).
• Known hypersensitivity to propranolol or to one or more of the excipients.
• Currently untreated pheochromocytoma.
• History of Prinzmetals angina.
• History of sick sinus syndrome or atrioventricular block.
• History of stroke or any previous cardiovascular event.
• History of neoadjuvant oncological treatment for suspected primary pancreatic cancer.
• Recent or present (within 3 months) use of propranolol or any other beta-blocker.
• Recent or present (within 3 months) use of any of the following medications: anxiolytics, calcium channel blockers, beta-adrenergic receptor agonist.
• Medical history that classifies the patient as frail or unsuitable for inclusion by the examining physician.
• Histopathological examination revealing benign lesion.
• Predictable poor compliance, due to pre-existing psychiatric disease, dementia or not able to read or speak sufficient Danish, resulting in not being able to provide a well-informed written consent.

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Treatment
• Allocation: Randomized
• Interventional Model: Parallel Assignment
• Masking: Triple

Number of Arms

2

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Experimental: Propranolol; Propranolol will be administered 40 mg twice daily (morning and evening) in 10 days prior to surgery for pancreatic cancer	Drug: Propranolol; Oral administration.; Other Names: Inderal; Propal
Placebo Comparator: Placebo; Placebo will be administered twice daily (morning and evening) in 10 days prior to surgery for pancreatic cancer.	Drug: Placebo; Oral administration.; Other Names: Inactive drug

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Preoperative anxiety	Assessed through the Hamilton Anxiety Rating Scale (HAMA) questionnaire	Obtained preoperatively at baseline (immediately after inclusion) and immediately after intervention (before surgery)
Preoperative anxiety and depression	Assessed through the Hospital Anxiety and Depression Scale (HADS) questionnaire	Obtained preoperatively at baseline (immediately after inclusion) and immediately after intervention (before surgery)
Preoperative quality of life	Preoperative quality of life assessed through the quality of life questionnaire.	Obtained preoperatively at baseline (immediately after inclusion) and immediately after intervention (before surgery)
Density and subtypes of tumor-infiltrating lymphocytes in the tumor microenvironment.	Histopathological assessment of the density and subtypes of tumor-infiltrating lymphocytes. Immunohistochemistry technique will be used.	Through study completion. At latest within 1 year from last participant completes trial.
Desmoplasia in the tumor microenvironment.	Histopathological assessment of desmoplasia in the tumor microenvironment. Immunohistochemistry technique will be used.	Through study completion. At latest within 1 year from last participant completes trial.
Neural markers in the tumor microenvironment.	Histopathological assessment of neural marker expression (e.g., NGF, BDNF, tyrosin hydroxylase) Immunohistochemistry technique will be used.	Through study completion. At latest within 1 year from last participant completes trial.
Adrenergic receptor (ADRB1&ADRB2) expression in the tumor microenvironment.	Histopathological assessment of the expression of adrenergic receptors (ADRB1 and ADRB2). Immunohistochemistry technique will be used for this purpose.	Through study completion. At latest within 1 year from last participant completes trial.
Spatial distribution of immune cells in the tumor microenvironment.	Spatial distribution of immune cells in the tumor microenvironment using Immunohistochemistry technique and NanoString GeoMx techniques will be used for this purpose.	Through study completion. At latest within 1 year from last participant completes trial.
Immune cells and subtypes in blood samples	Assessing the number and subsets of immune cells in the obtained blood samples before and after propranolol treatment and between the two arms (propranolol versus placebo). This will be examined through FlowCytometry.	Through study completion. At latest within 1 year from last participant completes trial.
Circulating tumor cells before and after intervention in blood samples.	Assessment of circulating tumor cells in blood samples before and after intervention.	Through study completion. At latest within 1 year from last participant completes trial.
RNA-level gene expression in blood samples.	RNA-level expression of genes related to immune-surveillance through NanoString nCounter technique.	Through study completion. At latest within 1 year from last participant completes trial.
Heart rate variability in both trial arms	Examining differences in heart rate variability among participants and between intervention and comparator group.	Through study completion, an average of 1 year.
Postoperative complications	Assessment of postoperative complications based on the Clavien-Dindo Score (CD) ranging from I to V, where I is any decline from normal postoperative course and V is death of patient.	After participant finishes trial and when last follow up (5 years from surgery) date is due.
Survival 30-days after surgery	Assessment of survival 30 days after surgery.	After participant finishes trial and when last follow up (5 years from surgery) date is due.
Survival 90-days after surgery	Assessment of survival 90 days after surgery.	After participant finishes trial and when last follow up (5 years from surgery) date is due.
Overall survival 1-year after surgery	Assessment of overall surival 1-year after surgery	After participant finishes trial and when last follow up (5 years from surgery) date is due.
Overall survival 3-years after surgery	Assessment of overall survival 3-years after surgery	After participant finishes trial and when last follow up (5 years from surgery) date is due.
Overall survival 5-years after surgery	Assessment of overall survival 5-years after surgery	After participant finishes trial and when last follow up (5 years from surgery) date is due.

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Safety of 40 mg propranolol twice daily on blood pressure.	Examining the safety of preoperative propranolol 40 mg twice daily prior to elective surgery for pancreatic cancer by continuous at-home measurements of blood pressure twice daily during the intervention period.	Through study completion, within 14 days after surgery.
Safety of 40 mg propranolol twice daily on heart rate.	Examining the safety of preoperative propranolol 40 mg twice daily prior to elective surgery for pancreatic cancer by continuous at-home measurements of heart rate twice daily during the intervention period.	Through study completion, within 14 days after surgery.

Other Outcome Measures

Outcome Measure	Measure Description	Time Frame
Feasibility of implementing preoperative propranolol in the preoperative setting for patients with pancreatic cancer using the APEASE framework.	Examining the feasibility and implementation of preoperative 40 mg propranolol twice daily in patients undergoing surgery for pancreatic cancer. Challenges in the implementation will be assessed through the use of the APEASE framework, which looks in to Acceptability, Practicability, Effectiveness, Affordability, Spill-over effects, and Equity.	Within 1 year from end of the trial.

Collaborators and Investigators

• Sponsor: Zealand University Hospital
• Collaborators: Rigshospitalet, Denmark
• Investigators: Principal Investigator: Ismail Gögenur, Professor, Center for Surgical Science, Zealand University Hospital

Publications and helpful links

Helpful Links

• Drug Information - Propranolol

Study record dates

Study Major Dates

• Study Start (Actual): March 20, 2024
• Primary Completion (Estimated): December 31, 2026
• Study Completion (Estimated): December 31, 2035

Study Registration Dates

• First Submitted: November 8, 2023
• First Submitted That Met QC Criteria: November 17, 2023
• First Posted (Actual): November 22, 2023

Study Record Updates

• Last Update Posted (Actual): March 28, 2024
• Last Update Submitted That Met QC Criteria: March 25, 2024
• Last Verified: November 1, 2023

More Information

Terms related to this study

• Keywords: Pancreatic Cancer; Propranolol; PDAC; Beta-Blockers
• Additional Relevant MeSH Terms: Digestive System Diseases; Neoplasms; Neoplasms by Site; Endocrine System Diseases; Digestive System Neoplasms; Endocrine Gland Neoplasms; Pancreatic Diseases; Pancreatic Neoplasms; Physiological Effects of Drugs; Adrenergic beta-Antagonists; Adrenergic Antagonists; Adrenergic Agents; Neurotransmitter Agents; Molecular Mechanisms of Pharmacological Action; Anti-Arrhythmia Agents; Antihypertensive Agents; Vasodilator Agents; Propranolol
• Other Study ID Numbers: EU CT 2023-506553-37-00

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: NO

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No
• product manufactured in and exported from the U.S.: No